Clinical Trial Update: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of INBRX-106 in combination with pembrolizumab for locally advanced or metastatic solid tumors, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• INBRX-106 (INBRX-106)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Inhibrx Biosciences, Inc | Conditions: Solid Tumor, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING